| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02111187 | Prostate Cancer | Drug: LDE225 | Sidney Kimmel Comprehensive Cancer Center | Phase 1 | 2014-04-01 | 2016-10-14 |
| NCT02195973 | Recurrent Ovarian Cancer | Drug: LDE225 | University of Alabama at Birmingham|Novartis Pharmaceuticals | Phase 1 | 2014-09-01 | 2017-02-06 |
| NCT01764776 | Normal Hepatic Function|Impaired Hepatic Function | Drug: LDE225 | Novartis Pharmaceuticals|Novartis | Phase 1 | 2013-03-01 | 2017-02-13 |
| NCT02086513 | Graft Versus Host Disease | Drug: LDE225 | Massachusetts General Hospital|Novartis | Phase 1 | 2014-04-01 | 2017-03-21 |
| NCT02254551 | Multiple Myeloma | Drug: LDE225|Drug: Bortezomib | SCRI Development Innovations, LLC|Novartis | Phase 2 | 2015-01-01 | 2016-12-23 |
| NCT01529450 | Basal Cell Carcinoma | Drug: LDE225 | Anne Chang|Novartis|Stanford University | | 2012-02-01 | 2016-11-23 |
| NCT02002689 | PTCH1 or SMO Activated Solid and Hematologic Tumors | Drug: LDE225 | Novartis Pharmaceuticals|Novartis | Phase 2 | 2014-02-01 | 2016-04-25 |
| NCT01954355 | Solid Tumor|Ovarian Cancer | Drug: LDE225|Drug: Paclitaxel | Swiss Group for Clinical Cancer Research | Phase 1 | 2013-09-01 | 2016-11-23 |
| NCT01208831 | Advanced Solid Tumor Cancers|Medulloblastoma|Basal Cell Carcinoma | Drug: LDE225 | Novartis Pharmaceuticals|Novartis | Phase 1 | 2010-10-01 | 2016-04-20 |
| NCT00880308 | Advanced Solid Tumor Cancers|Medulloblastoma|Basal Cell Carcinoma | Drug: LDE225 | Novartis Pharmaceuticals|Novartis | Phase 1 | 2009-03-01 | 2014-12-27 |
| NCT02151864 | Hepatocellular Carcinoma|Cirrhosis | Drug: LDE225 | Jason K. Sicklick, M.D.|Novartis Pharmaceuticals|University of California, San Diego | Phase 1 | 2014-07-01 | 2016-09-27 |
| NCT01487785 | Pancreatic Cancer | Drug: LDE225+gemcitabine | Novartis Pharmaceuticals|Novartis | Phase 1 | 2012-03-01 | 2016-01-24 |
| NCT01826214 | Acute Leukemias | Drug: LDE225 | Novartis Pharmaceuticals|Novartis | Phase 2 | 2013-05-01 | 2016-07-26 |
| NCT02027376 | Advanced Breast Cancer | Drug: LDE225|Drug: Docetaxel | Spanish Breast Cancer Research Group|Novartis | Phase 1 | 2014-05-01 | 2015-11-05 |
| NCT01125800 | Medulloblastoma|Rhabdomyosarcoma|Neuroblastoma|Hepatoblastoma|Glioma|Astrocytoma | Drug: LDE225 | Novartis Pharmaceuticals|Novartis | Phase 1|Phase 2 | 2011-02-01 | 2017-02-13 |
| NCT01579929 | Lung Cancer | Drug: LDE225, Etoposide and Cisplatin | Memorial Sloan Kettering Cancer Center|Novartis Pharmaceuticals | Phase 1 | 2012-04-01 | 2017-02-15 |
| NCT01694589 | Resectable Pancreatic Cancer | Drug: LDE-225 | Rutgers, The State University of New Jersey|Rutgers Cancer Institute of New Jersey|National Cancer Institute (NCI)|Novartis Pharmaceuticals | Early Phase 1 | 2012-11-01 | 2014-12-10 |
| NCT02138929 | Esophageal Cancer | Drug: Everolimus|Drug: LDE 225 | M.D. Anderson Cancer Center|Novartis|National Cancer Institute (NCI) | Phase 1 | 2014-11-01 | 2016-09-30 |
| NCT01456676 | Philadelphia Chromosome Positive Chronic Myelogenous Leukemia | Drug: Nilotinib + LDE225 | Novartis Pharmaceuticals|Novartis | Phase 1 | 2012-01-01 | 2016-09-01 |
| NCT01327053 | Basal Cell Carcinoma | Drug: LDE225 | Novartis Pharmaceuticals|Novartis | Phase 2 | 2011-06-01 | 2016-09-20 |
